Growth Perspectives: Key Highlights from DCAT 2024
Frost & Sullivan
APRIL 3, 2024
Fuelling Growth: Strategic Investments, Acquisitions, and Expansions Samsung Biologics unveiled plans to expand capacity and geographic reach by initiating the construction of Bio Campus II with a $6 billion investment scheduled to begin operations in 2025 while completing its CGMP antibody-drug conjugate manufacturing facility within 2024.
Let's personalize your content